Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study

Cancer

Volumn 123, Issue , 2017, Pages 5059-5078

  Momin, Behnoosh R ^a   Pinheiro, Paulo S ^b   Carreira, Helena ^c   Li, Chunyu ^a   Weir, Hannah K ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF NEVADA   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

cancer registries; hepatitis; liver; population based survival

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RISK FACTOR; SURVIVAL ANALYSIS; UNITED STATES; VERY ELDERLY; AFRICAN AMERICAN; CAUCASIAN; EPIDEMIOLOGY; ETHNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; REGISTER; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; REGISTRIES; UNITED STATES; YOUNG ADULT;

EID: 85037644100     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30820     Document Type: Article

References (46)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
2. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 1987;47:4967-4972.
3. Taylor-Robinson SD, Foster GR, Arora S, Gargreaves S, Thomas HC. Increase in primary liver cancer in the UK 1979-1994. Lancet. 1997;350:1142-1143.
4. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet. 1998;351:214-215.
5. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:817-823.
6. Weir HK, Thompson TD, Soman A, Moller B, Leadbetter S. The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer. 2015;121:1827-1837.
7. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2013 Incidence and Mortality Web-Based Report. Atlanta, GA: US Department of Health and Human Services; 2016.
8. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312-1337.
9. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-538.
10. Welzel TM, Graubard BI, Quraishi S, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108:1314-1321.
11. Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862-1868.
12. Allemani C, Weir HK, Carreira H, et al; CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977-1010.
13. Fritz AG, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
14. Young JL, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER Summary Staging Manual—2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001. NIH publication 01-4969.
15. Surveillance, Epidemiology, and End Results Program. Collaborative stage. http://seer.cancer.gov/tools/collabstaging/. Accessed April 1, 2016.
16. Pohar Perme M, Stare J, Estève J. On estimation in relative survival. Biometrics. 2012;68:113-120.
17. Spika D, Bannon F, Bonaventure A, et al. Life tables for global surveillance of cancer survival (the CONCORD programme): data sources and methods. BMC Cancer. 2017;17:159.
18. Rachet B, Maringe C, Woods LM, Ellis L, Spika D, Allemani C. Multivariable flexible modelling for estimating complete, smoothed life tables for sub-national populations. BMC Public Health. 2015;15:1240.
19. Corazziari I, Quinn MJ, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40:2307-2316.
20. Quaresma M, Coleman MP, Rachet B. Funnel plots for population-based cancer survival: principles, methods and applications. Stat Med. 2014;33:1070-1080.
21. Allemani C, Harewood R, Johnson C, et al. Population-based cancer survival in the United States: data, quality control, and statistical methods. Cancer. 2017;123:4982-4993.
22. Micheli A, Ciampichini R, Oberaigner W, et al; EUROCARE Working Group. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45:1017-1027.
23. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
24. Siegel AB, McBride RB, El-Serag HB, et al. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol. 2008;103:120-127.
25. Reid AE, Resnick M, Chang Y, Buerstatte N, Weissman JS. Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transpl. 2004;10:834-841.
26. Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116:1367-1377.
27. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502.
28. Kubo S, Hirohashi K, Tanaka H, et al. Risk factors for recurrence after resection of hepatitis C virus–related hepatocellular carcinoma. World J Surg. 2000;24:1559-1565.
29. Kubo S, Hirohashi K, Tanaka H, et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus–related hepatocellular carcinoma. Cancer. 2000;88:1016-1024.
30. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B–related hepatocellular carcinoma. J Hepatol. 2009;51:890-897.
31. Kubo S, Takemura S, Sakata C, Urata Y, Uenishi T. Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus. Liver Cancer. 2013;2:40-46.
32. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
33. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill Summ. 2009;58:1-27.
34. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162:397-406.
35. Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J Gastroenterol Hepatol. 2011;26:221-227.
36. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61:1-32.
37. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-357.
38. Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Press; 2010.
39. Moore MS, Ivanina E, Bornschlegel K, Qiao B, Schymura MJ, Laraque F. Hepatocellular carcinoma and viral hepatitis in New York City. Clin Infect Dis. 2016;63:1577-1583.
40. El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. Arch Intern Med. 2007;167:1983-1989.
41. Pinheiro PS, Sherman RL, Trapido EJ, et al. Cancer incidence in first generation U.S. Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos. Cancer Epidemiol Biomarkers Prev. 2009;18:2162-2169.
42. Pinheiro PS, Callahan KE, Siegel RL, et al. Cancer mortality in Hispanic ethnic groups. Cancer Epidemiol Biomarkers Prev. 2017;26:376-382.
43. Pinheiro PS, Callahan KE, Ragin CR, Hage RW, Hylton T, Kobetz EN. Black heterogeneity in cancer mortality: US-Blacks, Haitians, and Jamaicans. Cancer Control. 2016;23:347.
44. White MC, Babcock F, Hayes NS, et al. The history and use of cancer registry data by public health cancer control programs in the United States. Cancer. 2017;123:4969-4976.
45. El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Ther Adv Gastroenterol. 2011;4:5-10.
46. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758-2765.